Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019 |
| September 28, 2019 | September 2019 Bond Updates |
|
THOUSAND OAKS, Calif., Sept. 27, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors. The data include the first evidence of anti-tumor activity reported in... |
| View more at: https://www.prnewswire.com:443/news-releases/amgen-announces-new-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-in-patients-with-solid-tumors-at-esmo-2019-300927215.html |
| Related News |